PE-22-28
The Novel Anti-Depressant Peptide
01
Overview
PE-22-28 is a synthetic truncated analogue of spadin, which is itself a fragment of the TREK-1 potassium channel propeptide. Research shows it acts as a rapid-onset antidepressant with nootropic properties. Unlike classical antidepressants, it works through a unique mechanism involving TREK-1 channel blockade.
02
Mechanism of Action
PE-22-28 selectively blocks TREK-1 two-pore domain potassium channels. This blockade results in increased neuronal excitability in mood-regulating circuits and promotes hippocampal neurogenesis. Research shows activation of the BDNF-TrkB signaling pathway.
03
Research Highlights
Rapid antidepressant effects observed within days rather than weeks in animal models
Hippocampal neurogenesis demonstrated through BrdU incorporation studies
Synaptogenic effects comparable to BDNF administration in cortical neuron cultures
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue or intranasal. Research protocols typically use once-daily administration; timing independent of food.
Dosage Guidelines
Cycle Length
2–4 weeks; research is early-stage with limited long-term data.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 5 mg vial
Concentration
2.5 mg/mL (2,500 mcg/mL)
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
PE-22-28 is a spadin analog; research-stage compound with limited human data. Approach dosing conservatively.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
PE-22-28 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
PE-22-28 Knowledge Graph
Explore how PE-22-28 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
PE-22-28 — Common Research Questions
What is PE-22-28?
PE-22-28 is a synthetic truncated analogue of spadin, which is itself a fragment of the TREK-1 potassium channel propeptide. Research shows it acts as a rapid-onset antidepressant with nootropic prope... PE-22-28 belongs to the Cognitive research category and is studied for its the novel anti-depressant peptide.
How does PE-22-28 work?
PE-22-28 selectively blocks TREK-1 two-pore domain potassium channels. This blockade results in increased neuronal excitability in mood-regulating circuits and promotes hippocampal neurogenesis. Research shows activation of the BDNF-TrkB signaling pathway.
What are the key research benefits of PE-22-28?
Rapid antidepressant action in research models. TREK-1 channel blockade for mood modulation. Memory and cognitive enhancement. Neurogenesis promotion in the hippocampus. Synaptogenesis and BDNF upregulation. Potential PTSD and anxiety applications.
What is the molecular structure of PE-22-28?
PE-22-28 is a research compound in the Cognitive category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about PE-22-28?
Rapid antidepressant effects observed within days rather than weeks in animal models Hippocampal neurogenesis demonstrated through BrdU incorporation studies Synaptogenic effects comparable to BDNF administration in cortical neuron cultures These findings are based on preclinical and clinical research. PE-22-28 is a research compound and these studies do not constitute medical advice.
Is PE-22-28 FDA approved?
No. PE-22-28 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does PE-22-28 belong to?
PE-22-28 belongs to the Cognitive category, which focuses on peptides investigated for their nootropic and neuroprotective potential, supporting mental clarity, memory consolidation, and neurological resilience. You can explore more compounds in this category on the Cognitive pillar page.
Related Articles
Semax: BDNF Upregulation and Cognitive Enhancement
A review of Semax's mechanism — from melanocortin receptor modulation to BDNF and NGF upregulation in the hippocampus.
Dihexa: Synaptogenesis and Spatial Memory
Washington State University research on Dihexa's dramatic effects on synaptogenesis and Morris water maze performance.
Noopept: The Dipeptide Nootropic
Understanding Noopept's prodrug conversion, BDNF/NGF upregulation, and its position as a dipeptide nootropic.
Scientific References
Mazella et al. — "TREK-1 channel blockade and rapid antidepressant action" (Nature Neurosci, 2015)
Bhatt et al. — Hippocampal neurogenesis via spadin analogues, Neuropharmacology, 2017
Rapid antidepressant effects observed within days rather than weeks in animal models
Hippocampal neurogenesis demonstrated through BrdU incorporation studies
Synaptogenic effects comparable to BDNF administration in cortical neuron cultures